Status:
COMPLETED
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Lead Sponsor:
Tianjin SinoBiotech Ltd.
Collaborating Sponsors:
Peking University Cancer Hospital & Institute
Conditions:
Underdose (Unintentional)
Cancer
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.
Detailed Description
A dosage climbing for the safety and efficacy studies for the neutropenia induced by chemotherapy cancer patients Repeat-dose studies for the safety and efficacy studied for the neutropenia.
Eligibility Criteria
Inclusion
- \- chemotherapy induced neutropenia
Exclusion
- \- treated with other biological drugs or other neutropenia therapy drugs
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01919710
Start Date
October 1 2012
End Date
August 1 2014
Last Update
June 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China, 100142